Treatment-Resistant Hypertension - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight’s ‘Treatment-resistant Hypertension (RHTN) —Market Insights, Epidemiology, and Market Forecast—2032’ report deliver an in-depth understanding of Treatment-resistant Hypertension (RHTN), historical and forecasted epidemiology, as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Treatment-resistant Hypertension (RHTN) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted Treatment-resistant Hypertension (RHTN) symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Treatment-resistant Hypertension (RHTN) symptoms, treatment practice/algorithm, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019–2032

Treatment-resistant Hypertension (RHTN) Understanding and Treatment Algorithm

Treatment-resistant Hypertension (RHTN) Overview

Treatment-resistant Hypertension (RHTN) is defined as uncontrolled blood pressure despite the use of ≥3 antihypertensive agents of different classes, including a diuretic, usually thiazide-like, a long-acting calcium channel blocker, or a blocker of the renin–angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally tolerated doses.

Treatment-resistant Hypertension (RHTN) Diagnosis and Treatment

This section covers the details of diagnostic methods and conventional and current medical therapies available in the Treatment-resistant Hypertension (RHTN) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Treatment-resistant Hypertension (RHTN) market report gives a holistic understanding of Treatment-resistant Hypertension (RHTN) clinical manifestations by including disease definition, symptoms, causes, risk factors, physiology, and diagnosis. It also provides Treatment-resistant Hypertension (RHTN) treatment algorithms and treatment guidelines for Treatment-resistant Hypertension (RHTN) in the US, Europe, and Japan.

The main treatment strategies adopted for treatment-resistant hypertension include both nonpharmacological and pharmacological interventions. Nonpharmacological interventions include lifestyle modifications, DASH diet, reduced salt intake, restricted alcohol consumption, etc. Pharmacological interventions include withdrawal of interfering medication, optimization of diuretic therapy, mineralocorticoids, combination therapy, and the use of Spironolactone as the fourth agent for treating RHTN.

Treatment-resistant Hypertension (RHTN) Epidemiology

The Treatment-resistant Hypertension (RHTN) symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

Key Findings

The total prevalent cases of Treatment-resistant Hypertension (RHTN) patients in the 7MM increased during the study period, i.e., 2019–2032.

The disease epidemiology covered in the report provides historical as well as forecasted Treatment-resistant Hypertension (RHTN) symptoms epidemiology segmented as the Total Prevalent Cases, Gender-specific Cases, and Age-specific Cases. The report includes the prevalent cases scenario of Treatment-resistant Hypertension (RHTN) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Treatment-resistant Hypertension (RHTN) Epidemiology

The epidemiology segment also provides the Treatment-resistant Hypertension (RHTN) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total number of prevalent cases of Treatment-resistant Hypertension (RHTN) in 7MM countries was ~16.4 million in 2021.

Treatment-resistant Hypertension (RHTN) Drug Chapters

The Treatment-resistant Hypertension (RHTN) report’s drug chapter segment encloses the detailed analysis of Treatment-resistant Hypertension (RHTN) early-stage (Phase I, II, and III) pipeline drugs. It also helps understand the Treatment-resistant Hypertension (RHTN) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Treatment-resistant Hypertension (RHTN) Emerging Drugs

Aprocitentan: Idorsia Ltd/Janssen Biotech

Aprocitentan is an investigational, orally active dual endothelin receptor antagonist in development for the RHTN (individuals with uncontrolled hypertension despite the use of at least three antihypertensive drugs).

Firibastat (QGC001): Quantum Genomics SA

The firibastat (originally named QGC001) product is a prodrug that delivers in the brain the EC33 product, a selective and specific inhibitor of Aminopeptidase A, thus preventing the production of Angiotensin III in the brain. Due to its unique action mechanism, firibastat represents an alternative therapeutic approach that can interfere with the mechanism involved in the genesis and control of blood pressure in hypertensive patients, especially those with a particular hormonal profile, characterized by a low renin concentration and a high vasopressin concentration (Low Renin High Vasopressin (LRHV) profile). Firibastat and its therapeutic use are strongly protected by several families of patents ensuring industrial protection until 2033 without considering the potential additional protection certificates.

CIN-107: CinCor Pharma

CIN-107 is a highly selective aldosterone synthase inhibitor being developed for large unmet medical needs, including resistant hypertension and primary aldosteronism. CIN-107 works through the renin-angiotensin-aldosterone system (RAAS), which regulates the body’s fluid and electrolyte balance.

Other Products detailed in the report…

Treatment-resistant Hypertension (RHTN) Market Outlook

The report’s Treatment-resistant Hypertension (RHTN) market outlook helps understand the historic, current better, and forecasted Treatment-resistant Hypertension (RHTN) market trends by analyzing the impact of current therapies on the market, unmet needs, SWOT analysis, and demand for better technology.

At present, the therapeutic market size of RHTN is mainly comprised of pharmacological therapies and nonpharmacological therapies.

Nonpharmacological interventions include lifestyle modifications, a DASH diet, reduced salt intake, restricted alcohol consumption, etc. Pharmacological interventions include withdrawal of interfering medication, optimization of three-drug regimen and diuretic therapy, combination therapy, and addition of mineralocorticoid receptor antagonists (spironolactone) as the fourth agent for treating RHTN.

According to DelveInsight, the Treatment-resistant Hypertension (RHTN) market in 7MM is expected to grow steadily during the study period 2019–2032.

To meet the urgent need for novel medications to treat RHTN with different MoA, few promising therapies in development are firibastat (Quantum Genomics), aprocitentan (Idorsia Pharmaceuticals), CIN-107 (CinCor Pharma), IONIS-AGT-LRx (Ionis Pharmaceuticals), patiromer (Vifor Pharma), among others. Other promising therapies include device-based intervention, including renal denervation.

In a nutshell, it is estimated that the RHTN treatment space will experience significant changes during the forecast period of 2019–2032, owing to the launch of upcoming novel therapies and a robust pipeline of drugs in development for the management of RHTN. However, the challenges of pricing and reimbursement and associated side effects are two major factors likely to influence the market success of the upcoming therapies.

Key Findings

This section includes a glimpse of the Treatment-resistant Hypertension (RHTN) market in 7MM.

Treatment-resistant Hypertension (RHTN) market size in the seven major markets was over USD 13 billion in 2021.

The United States Market Outlook

This section provides the total Treatment-resistant Hypertension (RHTN) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Treatment-resistant Hypertension (RHTN) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

The United States accounts for the largest market size for Treatment-resistant Hypertension (RHTN), followed by Germany, the United Kingdom, France, Spain, and Italy.

Japan: Market Outlook

The total Treatment-resistant Hypertension (RHTN) market size and market size by therapies in Japan are provided in this section.

Treatment-resistant Hypertension (RHTN) Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers the Treatment-resistant Hypertension (RHTN) market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Treatment-resistant Hypertension (RHTN) Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Treatment-resistant Hypertension (RHTN) key players involved in developing targeted therapeutics.

Major market players include Quantum Genomics, Idorsia Pharmaceuticals, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, among others.

Pipeline Development Activities

The report covers collaborations, acquisitions, mergers, licensing, and patent details for Treatment-resistant Hypertension (RHTN) emerging therapies.

In March 2018, Vifor Pharma granted Zeria pharmaceutical exclusive rights to develop and commercialize Veltassa in Japan. Under the terms of the agreement, Zeria had the exclusive right to develop Veltassa for the Japanese market and, once marketing authorization is granted, to commercialize it in Japan. The collaboration with Zeria represents an important step in Vifor Pharma’s plan to launch Veltassa globally.

Reimbursement Scenario in Treatment-resistant Hypertension (RHTN)

Proactively approaching reimbursement can positively impact both during the early stages of product development and after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with better market access can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Treatment-resistant Hypertension (RHTN) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Treatment-resistant Hypertension (RHTN) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Treatment-resistant Hypertension (RHTN) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
The report covers the descriptive overview of Treatment-resistant Hypertension (RHTN), explaining its causes, signs and symptoms, physiology, and currently available therapies.
Comprehensive insight has been provided into the Treatment-resistant Hypertension (RHTN) epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for Treatment-resistant Hypertension (RHTN) is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
A detailed review of the Treatment-resistant Hypertension (RHTN) market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies by understanding trends shaping and driving the global Treatment-resistant Hypertension (RHTN) market.

Report Highlights
In the coming years, the Treatment-resistant Hypertension (RHTN) market is set to change due to the rising awareness of the disease, the development of diagnostic techniques, and the favorable environment from regulators for innovative first-in-class curative drugs that are likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence Treatment-resistant Hypertension (RHTN) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Major players are involved in developing therapies for Treatment-resistant Hypertension (RHTN). The launch of emerging therapies will significantly impact the Treatment-resistant Hypertension (RHTN) market.
Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Treatment-resistant Hypertension (RHTN) Report Insights
Patient Population
Therapeutic Approaches
Treatment-resistant Hypertension (RHTN) Pipeline Analysis
Treatment-resistant Hypertension (RHTN) Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Treatment-resistant Hypertension (RHTN) Report Key Strengths
11-year Forecast
7MM Coverage
Treatment-resistant Hypertension (RHTN) Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Treatment-resistant Hypertension (RHTN) Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness

Key Questions

Market Insights:
What was the Treatment-resistant Hypertension (RHTN) Market share (%) distribution in 2019, and how would it look in 2032?
What would be the Treatment-resistant Hypertension (RHTN) total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
What are the key findings of the market across 7MM, and which country will have the largest Treatment-resistant Hypertension (RHTN) market size during the forecast period (2019–2032)?
At what CAGR the Treatment-resistant Hypertension (RHTN) market is expected to grow by 7MM during the forecast period (2019–2032)?
What would be the Treatment-resistant Hypertension (RHTN) market outlook across the 7MM during the forecast period (2019–2032)?
What will be the Treatment-resistant Hypertension (RHTN) market growth until 2032, and what will be the resultant market size in 2032?

Epidemiology Insights:
What are the disease risk, burdens, and unmet needs of Treatment-resistant Hypertension (RHTN)?
What is the historical Treatment-resistant Hypertension (RHTN) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Treatment-resistant Hypertension (RHTN) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM concerning the patient population for Treatment-resistant Hypertension (RHTN)?
Out of all 7MM countries, which country would have the largest prevalent population of Treatment-resistant Hypertension (RHTN) during the forecast period (2019–2032)?
At what CAGR is the population expected to grow by 7MM during the forecast period (2019–2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
What are the current options for the treatment of Treatment-resistant Hypertension (RHTN) along with the approved therapy?
What are the current treatment guidelines for treating Treatment-resistant Hypertension (RHTN) in the US, Europe, and Japan?
What is the Treatment-resistant Hypertension (RHTN) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
How many companies are developing therapies for the treatment of Treatment-resistant Hypertension (RHTN)?
How many therapies are developed by each company for the treatment of Treatment-resistant Hypertension (RHTN)?
How many emerging therapies are in the mid-stage and late stages of development to treat Treatment-resistant Hypertension (RHTN)?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to Treatment-resistant Hypertension (RHTN) therapies?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
What clinical studies are going on for Treatment-resistant Hypertension (RHTN) and its status?
What have key designations been granted for the emerging therapies for Treatment-resistant Hypertension (RHTN)?
What are the global historical and forecasted markets for Treatment-resistant Hypertension (RHTN)?

Reasons to buy
The report will help develop business strategies by understanding trends shaping and driving the Treatment-resistant Hypertension (RHTN) market.
To understand the future market competition in the Treatment-resistant Hypertension (RHTN) market and an Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for Treatment-resistant Hypertension (RHTN) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
Organize sales and marketing efforts by identifying the best opportunities for the Treatment-resistant Hypertension (RHTN) market.
To understand the future market competition in the Treatment-resistant Hypertension (RHTN) market.